BR112016004118A2 - uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar - Google Patents

uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar

Info

Publication number
BR112016004118A2
BR112016004118A2 BR112016004118A BR112016004118A BR112016004118A2 BR 112016004118 A2 BR112016004118 A2 BR 112016004118A2 BR 112016004118 A BR112016004118 A BR 112016004118A BR 112016004118 A BR112016004118 A BR 112016004118A BR 112016004118 A2 BR112016004118 A2 BR 112016004118A2
Authority
BR
Brazil
Prior art keywords
acetyl
coa carboxylase
acne vulgaris
carboxylase inhibitors
treatment
Prior art date
Application number
BR112016004118A
Other languages
English (en)
Inventor
Elisabeth Sonnenberg Gabriele
Paul Esler William
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112016004118A2 publication Critical patent/BR112016004118A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

a presente invenção refere-se a métodos de tratamento e/ou prevenção da acne em pacientes, compreendendo a etapa de administração aos pacientes que precisam desse tratamento, de uma quantidade terapeuticamente eficaz de um inibidor da acc ou de um sal farmaceuticamente aceitável do mesmo.
BR112016004118A 2013-09-12 2014-08-29 uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar BR112016004118A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361877058P 2013-09-12 2013-09-12
PCT/IB2014/064151 WO2015036892A1 (en) 2013-09-12 2014-08-29 Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris

Publications (1)

Publication Number Publication Date
BR112016004118A2 true BR112016004118A2 (pt) 2017-10-17

Family

ID=51541122

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016004118A BR112016004118A2 (pt) 2013-09-12 2014-08-29 uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar

Country Status (17)

Country Link
US (1) US20160220557A1 (pt)
EP (1) EP3043800A1 (pt)
JP (1) JP2016534091A (pt)
KR (1) KR20160042089A (pt)
CN (1) CN105530940A (pt)
AR (1) AR097619A1 (pt)
AU (1) AU2014319990A1 (pt)
BR (1) BR112016004118A2 (pt)
CA (1) CA2923884A1 (pt)
HK (1) HK1217448A1 (pt)
IL (1) IL243969A0 (pt)
MX (1) MX2016002479A (pt)
RU (1) RU2016106829A (pt)
SG (1) SG11201600711PA (pt)
TW (1) TW201521722A (pt)
WO (1) WO2015036892A1 (pt)
ZA (1) ZA201601084B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147161A1 (en) * 2016-02-23 2017-08-31 Raju Mohan Treatment of dermatological disorders or conditions
EP3644998B1 (en) 2017-06-30 2024-04-10 Quixgen, Inc. Novel spirolactone compounds
WO2019072478A1 (en) 2017-10-10 2019-04-18 Galderma Research & Development SPECIFIC ACETYL-COA CARBOXYLASE INHIBITORS FOR USE IN THE TREATMENT AND / OR PREVENTION OF ACNE
TW201930265A (zh) 2017-12-11 2019-08-01 西班牙商阿爾米雷爾有限公司 作為acc抑制劑的吡咯衍生物
GB201812561D0 (en) * 2018-08-01 2018-09-12 Univ Manchester Biomarkers and uses thereof
WO2020245297A1 (en) 2019-06-06 2020-12-10 Almirall, S.A. Pyrrole derivatives as acc inhibitors
WO2020245291A1 (en) 2019-06-06 2020-12-10 Almirall, S.A. Pyrrole derivatives as acc inhibitors
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途
EP4014964A1 (en) 2020-12-21 2022-06-22 Almirall S.A. Topical formulation
WO2023090411A1 (ja) 2021-11-19 2023-05-25 塩野義製薬株式会社 心疾患または骨格筋の疾患の治療用医薬
WO2024023727A1 (en) * 2022-07-29 2024-02-01 Pfizer Inc. Novel acc inhibitors

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855897A (en) * 1996-09-13 1999-01-05 E-L Management Corp. Topical composition and method for enhancing lipid barrier synthesis
JPH11171847A (ja) 1997-09-26 1999-06-29 Fujirebio Inc ブタン酸アミド誘導体
JPH11171848A (ja) 1997-09-26 1999-06-29 Fujirebio Inc 芳香族アミド誘導体
US6120756A (en) * 1998-08-19 2000-09-19 Philip I. Markowitz Topical anionic salicylate for disorders of the skin
AU1485401A (en) 1999-11-12 2001-06-06 Johns Hopkins University School Of Medicine, The Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells
PE20030703A1 (es) * 2001-09-06 2003-08-21 Schering Corp Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
JP2005194191A (ja) 2001-12-28 2005-07-21 Ajinomoto Co Inc 抗肥満薬、脂肪肝治療薬
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
EP1478437B1 (en) 2002-02-27 2005-08-31 Pfizer Products Inc. Acc inhibitors
US6485941B1 (en) 2002-04-23 2002-11-26 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of the carboxyltransferase component of acetyl-CoA carboxylase, and the use of such inhibition in anti-cancer and anti-lipogenic therapies
US7211423B2 (en) 2004-07-23 2007-05-01 Bristol-Myers Squibb Co. Acetyl CoA carboxylase 2 sequences and methods
WO2006017494A2 (en) 2004-08-02 2006-02-16 Elizabeth Mazzio Inhibition of anaerobic glucose metabolism
US20060178400A1 (en) 2004-11-05 2006-08-10 Beutel Bruce A Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
AU2006235451A1 (en) 2005-04-08 2006-10-19 Isis Pharmaceuticals, Inc. Compositions and their uses directed to acetyl-CoA carboxylases
CA2617042A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
JP2007161630A (ja) * 2005-12-13 2007-06-28 Adeka Corp 皮脂抑制剤
CA2641734A1 (en) 2006-02-15 2007-08-23 Abbott Laboratories Acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
CA2641766A1 (en) 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2007095601A2 (en) 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
CA2648748A1 (en) 2006-04-14 2007-10-25 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US20100204317A1 (en) * 2006-11-03 2010-08-12 Qlt Inc. Methods of treating dermatological disorders or conditions
KR20080052024A (ko) 2006-12-07 2008-06-11 (주)아모레퍼시픽 아세틸-조효소 ａ 카복실라제 저해활성을 갖는트리아졸로피리다진 유도체
WO2008072850A1 (en) 2006-12-11 2008-06-19 Amorepacific Corporation Triazine derivatives having inhibitory activity against acetyl-coa carboxylase
US7928243B2 (en) 2006-12-21 2011-04-19 Abbott Laboratories Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP2008179621A (ja) 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
JPWO2008090944A1 (ja) 2007-01-25 2010-05-20 武田薬品工業株式会社 スピロ環化合物
JPWO2008102749A1 (ja) 2007-02-20 2010-05-27 武田薬品工業株式会社 複素環化合物
WO2008121592A2 (en) 2007-03-30 2008-10-09 Takeda Pharmaceutical Company Limited Acetyl coenzyme a carboxylase inhibitors
AU2008251742A1 (en) 2007-05-14 2008-11-20 Accera, Inc. Inhibitors of acetyl-CoA carboxylase for treatment of neuronal hypometabolism
JP5616220B2 (ja) 2007-06-01 2014-10-29 ザ トラスティーズ オブ プリンストン ユニバーシティ 宿主細胞代謝経路の調節によるウイルス感染治療
WO2009055682A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica N.V. Crystal structure of the carboxyl transferase domain of human acetyl-coa carboxylase 2 protein (acc2 ct) and uses thereof
JP2009196966A (ja) 2008-02-25 2009-09-03 Takeda Chem Ind Ltd ピラゾリジンジオン誘導体
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
ES2545231T3 (es) 2008-05-28 2015-09-09 Pfizer Inc. Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
EP2297164A1 (en) 2008-05-28 2011-03-23 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2729412A1 (en) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co., Ltd. Novel spirochromanone carboxylic acids
JP2010043019A (ja) 2008-08-12 2010-02-25 Taisho Pharmaceutical Co Ltd ピペリジニルピペラジン化合物
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
US20100113473A1 (en) 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
WO2010127208A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
US20100280067A1 (en) * 2009-04-30 2010-11-04 Pakala Kumara Savithru Sarma Inhibitors of acetyl-coa carboxylase
EP2451796B1 (en) 2009-07-08 2013-04-17 Dermira (Canada), Inc. Tofa analogs useful in treating dermatological disorders or conditions
AP3283A (en) 2009-11-10 2015-05-31 Pfizer N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
CN101876925B (zh) 2009-11-27 2012-05-02 成都市华为赛门铁克科技有限公司 内存镜像处理方法、装置和系统
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
DE102010008644A1 (de) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie
DE102010008642A1 (de) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie
DE102010008643A1 (de) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie
JP2011225455A (ja) 2010-04-15 2011-11-10 Kao Corp Ｓｒｅｂｐ抑制剤
TW201206911A (en) 2010-04-27 2012-02-16 Takeda Pharmaceutical Bicyclic compound
US9006450B2 (en) 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
US20120129833A1 (en) 2010-08-20 2012-05-24 Bayer Pharma Aktiengesellschaft Cyclic ketoenols for therapy
US8835472B2 (en) 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US8877754B2 (en) 2010-09-06 2014-11-04 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
KR20150006899A (ko) 2010-10-29 2015-01-19 화이자 인코포레이티드 N1/N2-락탐 아세틸-CoA 카복실라아제 억제제
SG190925A1 (en) 2010-11-30 2013-07-31 Takeda Pharmaceutical Bicyclic compound
WO2012090219A2 (en) 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
JP2014504624A (ja) 2011-02-06 2014-02-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 処置用の（５ｓ，８ｓ）−３−（４’−クロロ−３’−フルオロ−４−メチルビフェニル−３−イル）−４−ヒドロキシ−８−メトキシ−１−アザスピロ［４．５］デカ−３−エン−２−オン（化合物Ａ）
WO2012108478A1 (ja) 2011-02-09 2012-08-16 武田薬品工業株式会社 単環化合物
ME02312B (me) * 2011-04-22 2016-06-20 Pfizer DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE
DE102011080406A1 (de) 2011-08-04 2013-02-07 Bayer Pharma AG Substituierte 3-(Biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro8[4.5]dec-3-en-2-one
US8849404B2 (en) 2011-09-01 2014-09-30 Medtronic, Inc. Feedthrough assembly including a lead frame assembly
US20150246938A1 (en) 2011-09-09 2015-09-03 Shionogi & Co., Ltd. Novel olefin derivative
CN103998432A (zh) 2011-10-24 2014-08-20 武田药品工业株式会社 双环化合物
PL3628320T3 (pl) 2011-11-11 2022-07-25 Gilead Apollo, Llc Inhibitory acc i ich zastosowania
JP6129199B2 (ja) 2011-12-02 2017-05-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピペリジン誘導体、その医薬組成物及び使用
US8765959B2 (en) 2011-12-23 2014-07-01 Boehringer Ingelheim International Gmbh Piperidine derivatives
US8530461B2 (en) 2011-12-29 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
US8623860B2 (en) 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
CA2923884A1 (en) 2015-03-19
EP3043800A1 (en) 2016-07-20
SG11201600711PA (en) 2016-03-30
WO2015036892A1 (en) 2015-03-19
JP2016534091A (ja) 2016-11-04
CN105530940A (zh) 2016-04-27
MX2016002479A (es) 2016-05-31
HK1217448A1 (zh) 2017-01-13
IL243969A0 (en) 2016-04-21
AU2014319990A1 (en) 2016-02-25
ZA201601084B (en) 2017-05-31
TW201521722A (zh) 2015-06-16
KR20160042089A (ko) 2016-04-18
RU2016106829A (ru) 2017-10-17
AR097619A1 (es) 2016-04-06
US20160220557A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
BR112016004118A2 (pt) uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112016002465A2 (pt) terapia da combinação para o tratamento de câncer
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
WO2013024282A3 (en) Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer
BR112015023020A2 (pt) combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
EP4389225A3 (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
NZ629332A (en) Treatment of cancer with dihydropyrazino-pyrazines
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112014019399A2 (pt) métodos de tratamento da fibrose
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
BR112019008241A2 (pt) tratamento do prurigo nodular
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
BR112018069174A2 (pt) tratamento de prurido urêmico
BR112018002763A2 (pt) método para cicatrização de ferimentos
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2529 DE 25-06-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]